Interview with Dr. Thaïs Aliabadi, OB-GYN, on 6 Breast Changes We Should Never Ignore

A new breast lump is not the only change that deserves medical attention. Skin dimpling, a nipple that suddenly turns inward, nipple discharge, persistent nipple scaling, and changes in breast skin can also warrant evaluation. Dr. Thais Aliabadi and Mary Alice Haney discuss the ramifications of these issues. 

Most breast changes are not cancer, but we cannot reliably determine the cause at home. Our safest approach is to recognize what is different, contact a healthcare professional, and follow through on the recommended evaluation. Being young, having healthy habits, or having no family history should not be a reason to dismiss a new symptom.

In this interview-style discussion, we explore breast awareness, the six changes that need attention, and how breast density and lifetime breast cancer risk can help shape an individualized screening plan.

Table of Contents

• Recognizing the Six Breast Changes That Need Evaluation
• Turning a Breast Change Into a Clear Care Plan
• Understanding Our Normal Breast Appearance and Feel
• Looking Beyond Symptoms: Density and Lifetime Risk
• What Dr. Aliabadi’s Experience Teaches Us About Personalized Care

Recognizing the Six Breast Changes That Need Evaluation

What is the most important thing we should understand about breast cancer warning signs?

We should focus on change from our own usual appearance and feel, rather than trying to match every symptom to a particular diagnosis. Breast tissue varies from person to person. Some of us normally have more lumpiness, while others have nipples that have always pointed inward.

That baseline matters. A nipple that has been inverted throughout our lives is different from one that suddenly retracts. Familiar breast lumpiness is different from a distinct new mass. We do not need to become experts in diagnosing those differences, but we do need to bring them to a clinician’s attention.

The six changes we should report are:

1. A new or persistent breast lump.
2. Skin dimpling or an area that pulls inward.
3. A newly inverted nipple.
4. Nipple discharge, especially bloody discharge.
5. Persistent crusting, scaling, or flaking around the nipple.
6. New breast skin redness, swelling, or an orange-peel-like texture.

These are reasons for assessment, not proof that we have breast cancer. Keeping that distinction clear helps us act without assuming the worst.

1. What should we do if we discover a new breast lump?

We should arrange a medical evaluation for any new breast lump. An irregular mass that feels fixed in place is particularly concerning, but a lump does not have to fit that description to deserve attention.

A common mistake is assuming that a lump is harmless because it moves. Mobility alone does not give us a diagnosis. We should also avoid waiting for a lump to become painful before reporting it.

When contacting the office, we can describe where the lump is, when we first noticed it, and whether it feels different from the surrounding tissue. If it persists, that information is important even if we have otherwise familiar breast lumpiness.

We do not need to decide whether the lump feels sufficiently suspicious before asking for care. That assessment belongs with the healthcare team.

2. What does breast skin dimpling or pulling look like?

Dimpling means that part of the breast skin appears indented or drawn inward. We might notice a small depression or an area that no longer follows the breast’s usual contour.

This can be a visible change rather than something we feel as a lump. That is why breast awareness includes appearance as well as touch.

If we notice new pulling or dimpling, we should ask for an examination. We should not assume that the absence of a noticeable mass makes the skin change unimportant.

A useful description is specific: which breast is affected, where the indentation appears, and whether it is new. We can share those observations without trying to identify the underlying cause ourselves.

3. Is an inverted nipple always a warning sign?

No. Some of us naturally have inverted nipples, and that may be our normal anatomy. The important distinction is whether the nipple’s position has changed.

If a nipple previously pointed outward and now pulls inward, particularly on one side, we should seek prompt evaluation. We should not dismiss a newly retracted nipple simply because nipple inversion can sometimes be normal.

This illustrates why comparison with our own baseline is more useful than comparison with someone else’s breasts. We are looking for a new development, not a single appearance that is normal for everyone.

When arranging an appointment, we should make clear that the inversion is new. That detail helps distinguish an acquired change from a longstanding feature.

4. Which nipple discharge should we report?

We should tell our clinician about nipple discharge, with particular attention to any discharge that contains blood. Bloody nipple discharge deserves medical assessment even when we cannot feel a lump.

Discharge does not automatically mean cancer. However, we should not use that reassurance as a reason to ignore it. Our role is to describe the symptom clearly and let the clinician determine what evaluation is appropriate.

Helpful details include which breast is involved, what the fluid looks like, and when we first noticed it. If the pattern changes, we should report that too.

We should also avoid treating the six warning signs as a checklist that must occur together. Discharge alone can be enough reason to contact the office.

5. When should flaky or scaly nipple skin concern us?

Persistent crusting, scaling, flaking, or dryness of the nipple should be evaluated. The key issue is a change that continues rather than resolving.

It is easy to assume that every dry patch is a routine skin problem. But when the nipple’s appearance has changed and the change is not going away, we should have it examined rather than repeatedly guessing at the cause.

We can explain whether the skin change is new, whether it affects one or both nipples, and whether other changes are present. We do not need a lump, discharge, or pain to justify asking about persistent nipple scaling.

The goal is not to label every skin symptom as dangerous. It is to make sure a persistent change receives an explanation and an appropriate follow-up plan.

6. What breast skin color or texture changes need attention?

We should report new redness, swelling, warmth, or a change in the skin’s texture. One important example is peau d’orange, a French term describing skin that resembles the dimpled surface of an orange peel.

The term refers to texture, not simply orange-colored skin. That distinction matters because looking only for a particular color could cause us to overlook a change in the skin’s surface.

Orange-peel-like skin can be associated with inflammatory breast cancer, a rare but aggressive form of the disease. Redness, warmth, and tenderness can also occur with infection, including mastitis during breastfeeding.

We cannot reliably separate these possibilities by appearance alone. New or persistent breast skin changes need clinical assessment, particularly when they are not going away.

Turning a Breast Change Into a Clear Care Plan

What should we do first when we notice something different?

We should contact a primary care clinician, family physician, or gynecologist and explain that we have a new breast symptom. That is more useful than simply requesting our next routine screening appointment.

We can organize the conversation into four practical steps:

1. Name the change. Describe a lump, indentation, nipple change, discharge, scaling, or skin change.
2. Locate it. Identify the affected breast and the specific area.
3. Explain the timing. State when we noticed it and whether it is persisting or changing.
4. Ask for the next step. Clarify whether we need an examination, imaging, or another assessment, and how results will be communicated.

This approach helps us move from worry to an actionable plan. We do not have to use medical terminology. A straightforward description of what is different is enough to begin the conversation.

Should we wait until our next mammogram if we have a new symptom?

We should not treat our routine screening schedule as a reason to postpone reporting a new abnormality. Screening without symptoms and evaluating a symptom are different situations.

This distinction is especially important when we are younger than the usual age for routine mammograms. An age-based screening recommendation does not mean a younger person’s lump or nipple change should be ignored.

Our clinician can determine which assessment is appropriate. We should not assume that every symptom requires the same test, but we should expect the symptom to be taken seriously.

Similarly, if we recently had reassuring imaging, we should still mention a new or persistent change. We need a plan that addresses the concern we have now, not only a reminder of our previous result.

What if we are told that we are too young or too healthy to need evaluation?

We can ask how the clinician is accounting for the actual symptom. Breast cancer is uncommon at young ages, but age alone does not establish that a breast change is harmless.

A useful way to keep the discussion focused is to explain that this finding is different from our baseline and ask what assessment or follow-up will address it. If the concern remains unresolved or is being dismissed without an adequate explanation, we can seek a second opinion.

Advocacy does not require demanding one particular test or assuming that cancer is present. It means ensuring that the new finding has been considered and that we understand the plan.

We should leave the appointment knowing what happens next, who will contact us, and what to do if the change continues.

Understanding Our Normal Breast Appearance and Feel

How is breast self-awareness different from a monthly self-exam?

Breast self-awareness means becoming familiar with our breasts’ usual appearance and feel without relying on a rigid examination ritual.

Historically, many of us were taught a formal monthly self-exam with a prescribed pattern and date. The emphasis has shifted because routine structured self-exams have not shown the hoped-for improvement in earlier diagnosis or mortality.

That does not mean we should ignore our breasts. We can still notice their usual shape, nipple position, skin appearance, and texture through ordinary activities such as dressing or bathing.

We are not trying to perform a perfect examination or prove that no cancer exists. We are developing enough familiarity to recognize a meaningful difference and report it.

Breast awareness complements medical care and recommended imaging. It does not replace either one.

How can menstrual changes make breast symptoms confusing?

Before a period, breasts can become more swollen, tender, or lumpy. Age, hormone use, and fibrocystic changes can also influence how breast tissue feels.

We should consider that context, but avoid automatically attributing every new finding to hormones. A distinct new lump, persistent skin change, or newly inverted nipple still deserves attention.

The useful question is not whether breasts can change during a menstrual cycle. They can. The question is whether the finding fits our familiar pattern or is different from what we usually experience.

We can tell the clinician where we are in our cycle and how the current symptom compares with prior cycles. That history can help with interpretation without becoming a reason to delay needed care.

Does breast pain tell us whether a change is cancerous?

No. Many breast cancers are not painful, but breast cancer can sometimes cause pain. We should not use either the presence or absence of pain as a reliable way to classify a breast change.

For example, a painless lump still needs assessment. A painful lump should not automatically be dismissed as benign. Tenderness with redness and warmth may occur with infection, but it still needs appropriate care.

We should describe pain as part of the overall picture rather than treating it as the deciding factor.

The same principle applies to other individual features. No single observation at home, including mobility, tenderness, or a familiar-looking rash, can substitute for clinical evaluation of a concerning change.

Looking Beyond Symptoms: Density and Lifetime Risk

Why should we know our breast density?

Breast density is an imaging finding, not a description of breast size. We cannot determine it from how large, firm, or lumpy our breasts seem.

Density reflects the relative amounts of fatty tissue and fibrous and glandular tissue. We can find the reported density in our mammogram results.

It matters for two separate reasons:

• Dense tissue can make mammograms harder to interpret. Dense tissue and cancer can both appear white, allowing an abnormality to blend into surrounding tissue.
• Dense breast tissue is itself associated with increased breast cancer risk. This is separate from the difficulty of seeing through it on imaging.

We should discuss density alongside our other risk factors rather than treating it as an isolated result. Our guide to understanding breast density notifications after mammograms explains why this finding belongs in the screening conversation.

How do mammograms, ultrasound, and MRI fit together?

These tests provide different ways of evaluating breast tissue. A 3D mammogram allows the radiologist to examine thin image slices, helping reduce the problem of overlapping tissue that occurs with a two-dimensional image.

Ultrasound can provide another view of breast tissue and may be considered as supplemental imaging, including in discussions about dense breasts. It is not a replacement for mammography.

Breast MRI can form part of a more intensive screening plan for people at elevated risk. The appropriate combination depends on the overall clinical picture, not simply a desire to have every available test.

We can ask which test is being recommended, what question it is intended to answer, and whether it is screening or evaluating a symptom. For more detail, our explanation of when breast ultrasound may complement mammograms addresses that distinction.

What is a lifetime breast cancer risk assessment?

A lifetime risk assessment estimates our chance of developing breast cancer over time using information about our personal and family history. It is not a test that determines whether cancer is present today.

The Tyrer-Cuzick model is one tool used for this purpose. Its questions can include:

• Age, height, and weight.
• Age at the first menstrual period and menopause, when applicable.
• Pregnancy history.
• Hormone replacement therapy history.
• Breast density, when known.
• Previous breast biopsies and their findings.
• Family history of breast and ovarian cancer.

Before completing an assessment, we should gather our mammogram and biopsy reports when available. Describing a prior biopsy only as “not cancer” can leave out an important finding, such as atypical hyperplasia.

If density is unknown because we have not had a mammogram, the assessment discussed here can be completed without that information. We should review the result with a clinician rather than guessing at missing answers.

How can the result change our screening plan?

Risk assessment can help identify people who may benefit from earlier or more intensive screening than an average-risk schedule provides.

The categories discussed in this approach are below 15% lifetime risk for average risk, 15% to below 20% for intermediate risk, and 20% or more for high risk. These estimates guide a conversation; they do not independently prescribe every detail of care.

For high-risk patients, Dr. Aliabadi describes considering imaging earlier and alternating mammography-based screening with MRI so that an imaging assessment occurs approximately every six months.

She also describes earlier baseline imaging and periodic MRI for some intermediate-risk patients as preferences within her practice. Those practice choices should not be confused with a universal schedule for everyone.

We should ask when to begin, which tests to use, and how often to repeat them based on our individual history. A new symptom still needs evaluation regardless of the calculated percentage.

Does family history on our father’s side count?

Yes. We should gather information from both our maternal and paternal relatives. Breast cancer risk is not inherited only through the mother’s side of the family.

We should also avoid the opposite mistake: assuming that no family history means no meaningful risk. Many people who develop breast cancer do not have an affected relative.

When preparing for a risk discussion, we can collect the types of cancer in the family and ages at diagnosis when known. Breast and ovarian cancer are relevant to the Tyrer-Cuzick assessment. A broader genetic discussion may also consider cancers such as pancreatic, prostate, and colon cancer.

Family history is important, but it is one part of the picture alongside biopsy findings, breast density, genetics, and other personal factors.

What Dr. Aliabadi’s Experience Teaches Us About Personalized Care

Why did atypical hyperplasia change the understanding of her risk?

At age 48, Dr. Aliabadi had dense breasts and was undergoing mammography and ultrasound. A biopsy identified atypical lobular hyperplasia, an abnormal breast cell finding associated with a higher future risk of breast cancer.

Although the finding was not cancer, entering that biopsy history into a risk calculation produced an estimated lifetime risk of approximately 37.5%. Her lack of family history and negative testing for major inherited mutations had not captured that elevated risk.

We can draw an important distinction from this experience: removing an area of atypia and obtaining clear margins does not necessarily erase the broader risk associated with the biopsy history.

That is why we should obtain the actual pathology report and ask what the result means for future surveillance and risk-reduction options, not only whether the sampled tissue contained cancer.

Does her decision mean we should choose preventive mastectomy if our risk is elevated?

No. Her decision was individual and followed discussions about medication, surveillance, and surgery. She tried tamoxifen but experienced symptoms she found intolerable, then pursued bilateral mastectomy with reconstruction.

Pathology after surgery unexpectedly identified breast cancer in the opposite breast from the one that had undergone evaluation for atypia, despite reassuring imaging before surgery.

Her recovery also involved serious bleeding, blood transfusion, and a difficult postoperative course. We should not minimize those complications or present mastectomy as a simple solution to screening anxiety.

The practical lesson is to seek a careful discussion of benefits, limitations, complications, and alternatives with an experienced team. Her account of choosing an elective double mastectomy provides further context for that personal decision.

What should we understand about genetic testing and polygenic risk scores?

Testing for inherited cancer susceptibility can identify important variants in genes such as BRCA1, BRCA2, CHEK2, and PALB2. However, a negative result does not rule out breast cancer or account for every source of risk.

A polygenic risk score considers the combined influence of many smaller DNA variations rather than focusing only on major inherited variants. Dr. Aliabadi describes receiving a high breast cancer risk result through this type of assessment after her diagnosis.

We should view polygenic scoring as an evolving area to discuss with an appropriate clinician, not as a stand-alone diagnosis or an automatic requirement for everyone. Cost and insurance coverage can also be barriers.

If relatives carry a known BRCA variant and we test negative for that specific variant, the result needs careful interpretation. It does not remove the need to consider breast density, prior biopsies, and the rest of our medical history.

What habits or assumptions can interfere with early detection?

Several reassuring-sounding assumptions can delay an appropriate assessment:

• “We have no family history.” That does not exclude breast cancer.
• “The lump moves.” A movable lump can still require evaluation.
• “There is no pain.” Many breast cancers are painless.
• “It hurts, so it cannot be cancer.” Pain does not reliably exclude cancer either.
• “We are not old enough for mammograms.” A symptom needs its own assessment.
• “Our genetic test was negative.” Other risk factors still matter.
• “A recent scan was normal.” A new or persistent concern still deserves discussion.

Healthy habits remain valuable, but they do not provide immunity. We need both risk awareness and a willingness to act when something changes.

What should we take away from this conversation?

We can organize breast health around three responsibilities: recognize our baseline, understand our risk, and follow up on changes.

That means reporting a new lump, dimpling, nipple retraction, discharge, persistent nipple scaling, or new skin changes. It also means reviewing our breast density, gathering accurate family and biopsy histories, and asking whether our screening plan fits our risk.

We do not need to diagnose ourselves or assume that every change is cancer. We do need an explanation and a clear plan when something is different. If our concern is dismissed without being adequately addressed, seeking another opinion is a reasonable next step.

This discussion is educational and does not replace individualized medical advice. We should consult a healthcare professional about new breast symptoms, risk assessment, and screening decisions.